SCHEMBL2176669

SCHEMBL2176669

Cc1ccc(S(=O)(=O)Nc2cccc(Cl)c2C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.61
ALDH1A1 P00352 5/20 0.61
MAPT P10636 5/20 0.61
CYP2C9 P11712 2/20 0.61
CYP2C19 P33261 2/20 0.61
POLB P06746 2/20 0.61
USP2 O75604 1/20 0.61
NOD2 Q9HC29 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
FFAR4 Q5NUL3 1/20 0.59
KEAP1 Q14145 1/20 0.57
NFE2L2 Q16236 1/20 0.57
CA2 P00918 2/20 0.56
CA9 Q16790 2/20 0.56
CA1 P00915 1/20 0.56
CA4 P22748 1/20 0.56
CA7 P43166 1/20 0.56
CA12 O43570 1/20 0.55
MCOLN3 Q8TDD5 1/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175966 0.88 TSHR (0.72) LMNAALDH1A1MAPTPOLBKEAP1
SCHEMBL30557370 0.87 TSHR (0.71) LMNAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL7592222 0.87 TSHR (0.71) LMNAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL28605728 0.86 ALDH1A1 (0.59) LMNAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL12407072 0.85 MAPT (0.54) LMNAALDH1A1MAPTPOLBL3MBTL1
SCHEMBL31402302 0.84 KMT2A (0.59) LMNAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL12406982 0.84 PTGES2 (0.56) LMNAALDH1A1MAPTCYP2C9POLB
SCHEMBL12485134 0.84 GLO1 (0.54) LMNAALDH1A1MAPTPOLBGAA
SCHEMBL12406980 0.84 MAPT (0.53) LMNAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL2178383 0.84 KDM4E (0.58) LMNAALDH1A1MAPTPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 LMNA 4123/4885ALDH1A1 511/4885MAPT 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.